Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

References

• ValletSSmithMRRajeNNovel bone-targeted strategies in oncologyClin Cancer Res201016164084409320643782
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• GralowJRBiermannJSFarookiANCCN task force report: bone health in cancer careJ Natl Compr Canc Netw20097Suppl 3S1S32 quiz S33–3519555589
   PubMed Web of Science ®Google Scholar
• NIHConsensus Development Panel on Osteoporosis. Osteoporosis prevention, diagnosis, and therapyJAMA2001285678579511176917
   PubMedGoogle Scholar
• CornuzJFeskanichDWillettWCColditzGASmoking, smoking cessation, and risk of hip fracture in womenAm J Med1999106331131410190380
   PubMed Web of Science ®Google Scholar
• FeskanichDWillettWColditzGWalking and leisure-time activity and risk of hip fracture in postmenopausal womenJAMA2002288182300230612425707
   PubMed Web of Science ®Google Scholar
• MoayyeriAThe association between physical activity and osteoporotic fractures: a review of the evidence and implications for future researchAnn Epidemiol2008181182783518809340
   PubMed Web of Science ®Google Scholar
• Committee to Review Dietary Reference Intakes for Vitamin D and CalciumDietary Reference Intakes for Calcium and Vitamin DWashington, DCThe National Academies Press2011
   Google Scholar
• FavusMJBisphosphonates for osteoporosisN Engl J Med2010363212027203521083387
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJAMA1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianSZoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJ Clin Oncol200321163150315712915606
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• BoyleWJSimonetWSLaceyDLOsteoclast differentiation and activationNature2003423693733734212748652
   PubMed Web of Science ®Google Scholar
• BaronRFerrariSRussellRGDenosumab and bisphosphonates: different mechanisms of action and effectsBone201148467769221145999
   PubMed Web of Science ®Google Scholar
• FizaziKLiptonAMarietteXRandomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonatesJ Clin Oncol200927101564157119237632
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• HenryDHCostaLGoldwasserFRandomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaJ Clin Oncol20112991125113221343556
   PubMed Web of Science ®Google Scholar
• AdlerRAGillRSClinical utility of denosumab for treatment of bone loss in men and womenClin Interv Aging2011611912421753866
   PubMed Web of Science ®Google Scholar
• GoodwinPJEnnisMPritchardKITrudeauMHoodNRisk of menopause during the first year after breast cancer diagnosisJ Clin Oncol19991782365237010561298
   PubMed Web of Science ®Google Scholar
• BinesJOleskeDMCobleighMAOvarian function in premenopausal women treated with adjuvant chemotherapy for breast cancerJ Clin Oncol1996145171817298622093
   PubMed Web of Science ®Google Scholar
• ShapiroCLManolaJLeboffMOvarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancerJ Clin Oncol200119143306331111454877
   PubMed Web of Science ®Google Scholar
• BursteinHJPrestrudAASeidenfeldJAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancerJ Clin Oncol201028233784379620625130
   PubMed Web of Science ®Google Scholar
• SmithIEDowsettMAromatase inhibitors in breast cancerN Engl J Med2003348242431244212802030
   PubMed Web of Science ®Google Scholar
• AmirESerugaBNiraulaSCarlssonLOcanaAToxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysisJ Natl Cancer Inst2011103171299130921743022
   PubMed Web of Science ®Google Scholar
• EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• BrufskyAMBossermanLDCaradonnaRRZoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up resultsClin Breast Cancer200992778519433387
   PubMed Web of Science ®Google Scholar
• EidtmannHde BoerRBundredNEfficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST StudyAnn Oncol201021112188219420444845
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBStoegerHAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialLancet Oncol201112763164121641868
   PubMed Web of Science ®Google Scholar
• ColemanREMarshallHCameronDBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med2011365151396140521995387
   PubMed Web of Science ®Google Scholar
• SchramekDLeibbrandtASiglVOsteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerNature201046873209810220881962
   PubMed Web of Science ®Google Scholar
• JonesDHNakashimaTSanchezOHRegulation of cancer cell migration and bone metastasis by RANKLNature2006440708469269616572175
   PubMed Web of Science ®Google Scholar
• MohlerJBahnsonRRBostonBNCCN clinical practice guidelines in oncology: prostate cancerJ Natl Compr Canc Netw20108216220020141676
   PubMed Web of Science ®Google Scholar
• PayneHMasonMAndrogen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developmentsBr J Cancer2011105111628163422009028
   PubMed Web of Science ®Google Scholar
• LeeRJSaylorPJSmithMRTreatment and prevention of bone complications from prostate cancerBone2011481889520621630
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoYFFreemanJLGoodwinJSRisk of fracture after androgen deprivation for prostate cancerN Engl J Med2005352215416415647578
   PubMed Web of Science ®Google Scholar
• SmithMRLeeWCBrandmanJWangQBottemanMPashosCLGonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancerJ Clin Oncol200523317897790316258089
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBHernandez TorizNDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med2009361874575519671656
   PubMed Web of Science ®Google Scholar
• SmithMRSaadFColemanRDenosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialLancet20123799810394622093187
   PubMed Web of Science ®Google Scholar
• Task ForceAmerican Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jawsJ Oral Maxillofac Surg200765336937617307580
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRSystematic review: bisphosphonates and osteonecrosis of the jawsAnn Intern Med20061441075376116702591
   PubMed Web of Science ®Google Scholar
• SaadFBrownJEVan PoznakCIncidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesAnn Oncol20122351341134721986094
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• PapapoulosSChapurlatRLibanatiCFive years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJ Bone Miner Res2012273649701
   Web of Science ®Google Scholar
• WongBRRhoJArronJTRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cellsJ Biol Chem19972724025190251949312132
   PubMed Web of Science ®Google Scholar
• KongYYYoshidaHSarosiIOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature199939767173153239950424
   PubMed Web of Science ®Google Scholar
• AnastasilakisADToulisKAGoulisDGEfficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysisHorm Metab Res2009411072172919536731
   PubMed Web of Science ®Google Scholar
• WattsNBRouxCModlinJFInfections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Osteoporos Int201223132733721892677
   PubMed Web of Science ®Google Scholar
• PazianasMCooperCEbetinoFHRussellRGLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosisTher Clin Risk Manag2010632534320668715
   PubMed Web of Science ®Google Scholar
• IbrahimAScherNWilliamsGApproval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastasesClin Cancer Res2003972394239912855610
   PubMed Web of Science ®Google Scholar
• ChangJTGreenLBeitzJRenal failure with the use of zoledronic acidN Engl J Med20033491716761679 discussion 1676–167914573746
   PubMed Web of Science ®Google Scholar